Business Context and Reporting Period
This Form 6-K filing by Apollomics Inc. covers the month of November 2025, with a report date of November 17, 2025. The filing primarily addresses corporate governance changes, specifically the resignation of a director and the appointment of a new director to the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Director Resignation: Mr. Po-Jen Hsueh resigned from the Board of Directors on November 16, 2025. The resignation was not related to any disagreement with the Company.
- Director Appointment: Dr. Ya-Chi (Claudia) Huang was appointed to the Board on November 16, 2025, to fill the vacancy left by Mr. Hsueh.
- Committee Assignments: Dr. Huang replaces Mr. Hsueh as a member of the Audit Committee and the Nominating and Corporate Governance Committee.
- Board Composition: The Board now consists of seven members: Hung-Wen (Howard) Chen (Chairman), Hong-Jung (Moses) Chen, Yi-Kuei Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang. Five of these members are independent directors.
Outlook, Risks, and Management Commentary
The filing includes biographical information for the new director, Dr. Huang, highlighting her extensive experience in biotechnology investment, corporate governance, and R&D. She currently serves as Assistant Vice President at Maxpro Ventures and previously held roles at Diamond Biofund and Fubon Securities. Her scientific background includes a Ph.D. in Microbiology from National Taiwan University College of Medicine. No specific guidance, risks, contingencies, or unusual financial items were disclosed in this filing.
Key Facts for Investor Verification
- Verify the independence status of the five independent directors listed in the updated Board composition.
- Review the attached press release (Exhibit 99.1) for additional details on the Board changes.
- Confirm that the resignation of Mr. Hsueh had no undisclosed implications for ongoing operations or strategy.
- Note that this filing does not update the company's financial position; refer to the most recent Form 20-F for financial data.